Hemostemix - HMTXF STOCK NEWS

Hemostemix (TSXV: HEM) (OTC: HMTXF) has announced that its common share purchases can now be settled via the Depository Trust Company (DTC). The company filed a disclosure document with OTC Markets on January 7, 2025, and expects to receive OTCIQ access and begin trading on the OTCQB exchange later in January 2025.

The company has also entered into a 12-month agreement with biotech.de until December 31, 2025, to expand its reach to German-speaking investors. The services include German translation of news and social media, co-marketing, video production, investor introductions, and content creation to promote ACP-01 therapy for various conditions including PAD, CLTI, Angina, and various cardiac conditions. Biotech.de will receive compensation of $50,000 in Hemostemix common shares, issued quarterly at market price.

Hemostemix (HMTXF) has amended its Manufacturing Services Agreement with CytoImmune Therapeutics, adding Regulatory Consulting and Engineering Services. The agreement aligns with TSX Venture Exchange policies and Puerto Rico's ACT 60 Program. CytoImmune's regulatory expert, with FDA experience, will advise on regulatory strategy and clinical trials.

The partnership focuses on advancing Hemostemix's Automated Cell Therapy System (ACTS), capable of producing up to 2,880 ACP-01 therapies annually per clean room. At 80% efficiency with 10 production cells, the system could deliver 23,040 therapies yearly, priced at USD $37,000 each. The companies are studying production capacity at CytoImmune's 38,000-square-foot facility in San Juan.

Under the revised agreement, Hemostemix PR Inc. will make cash payments to CytoImmune, which will reinvest in Hemostemix's equity at market value. ACP-01 therapies target conditions including Peripheral Arterial Disease, Diabetic Foot Ulcers, and Critical Limb-Threatening Ischemia.

Hemostemix (TSXV: HEM) (OTC: HMTXF) has incorporated Hemostemix PR Inc. in Puerto Rico as a wholly owned subsidiary. Under Puerto Rico's ACT 60 program, the company is eligible for up to 50% cash reimbursement of R&D expenses, including clinical trials and economic impact assessments.

The company identifies an annual addressable market of 8,681 Diabetic Foot Ulcers treatments in Puerto Rico, valued at USD $37,000 each. This is based on Puerto Rico's diabetes prevalence of 19-20% among adults, affecting approximately 413,400 cases.

Clinical trial results show that ACP-01, the company's precision healthcare treatment, demonstrated significant efficacy: ulcer size decreased from 1.46 cm² to 0.48 mm² within three months in CLTI patients. In heart failure trials, ACP-01 improved cardiac function by up to 24.1% in ischemic cardiomyopathy and 47.1% in non-ischemic dilated cardiomyopathy patients at 12 months.

Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) has announced its application to up-list to the OTCQB Venture Market to increase liquidity across USA, European, and Canadian markets. The company is promoting its ACP-01 therapy through social media, highlighting successful patient treatments for limb salvation, heart function regeneration, and vascular dementia.

Clinical results show significant efficacy: 83% of patients in a Phase II trial experienced healing of ulcers and resolution of ischemic rest pain over 4.5 years. In dilated cardiomyopathy patients, cardiac function improved by up to 47.1% after one treatment. The Phase II results demonstrated ulcer size reduction from 1.46 cm² to 0.48 mm² within three months (p = 0.01).

The company addresses a significant market, with 236 million people suffering from peripheral arterial disease, of which 23 million develop chronic limb threatening ischemia with a 60% five-year mortality rate.

Hemostemix (TSXV: HEM) (OTC: HMTXF) announces growing traction in its social media awareness campaign across multiple platforms, promoting its trademarked "Your Fountain of Youth"™ regenerative medicine treatments. The campaign shares patient success stories and educates about innovative treatments for no-option cardiovascular diseases.

The company's ACP-01 treatment, derived from patients' blood and cultured in their serum, has shown significant results:

• In dilated cardiomyopathy patients, cardiac function improved by up to 47.1% after one treatment
• For Chronic Limb Threatening Ischemia (CLTI), 83% of patients followed for up to 4.5 years experienced healing of ulcers and pain resolution
• Ulcer size decreased significantly from 1.46 cm² to 0.48 mm² within three months in phase II trials

Hemostemix (TSXV: HEM) (OTC: HMTXF) has launched a comprehensive social media campaign across Instagram, Facebook, LinkedIn, YouTube, and X to showcase patient success stories and educate about their regenerative medicine treatments. The company's flagship treatment, ACP-01, derived from patients' own blood and cultured in their serum, has demonstrated significant clinical results:

In dilated cardiomyopathy patients, cardiac function improved by up to 47.1% after one treatment, with notable improvements in severe cases. For Chronic Limb Threatening Ischemia (CLTI) patients, 83% experienced healing of ulcers and resolution of ischemic rest pain in follow-ups up to 4.5 years. Ulcer size decreased significantly from 1.46 cm² to 0.48 mm² within three months.

Hemostemix has announced an update to its second closing, adding a $50,000 subscription to reach total gross proceeds of $2,725,981.77 through the issuance of 54,519,635 Units. The company paid finder fees of approximately $28,820.64 and issued 576,413 finder's options exercisable at $0.05 per Common Share within 24 months.

The offering includes participation from company directors, constituting a related party transaction under MI 61-101. The company is exempt from formal valuation and minority shareholder approval requirements as the transaction value does not exceed 25% of market capitalization. All securities issued will have a four-month hold period from the closing date.

Hemostemix has completed its second and final tranche of private placement, raising $833,258 through the issuance of 16,665,160 Units at $0.05 per Unit. The combined offerings totaled $2,675,981.77 with 53,519,635 Units issued. Each Unit includes one common share and one warrant exercisable at $0.12 per share for 24 months. The proceeds will fund the company's stem cell therapeutics platform, initiate ACP sales, and cover operational expenses. The company paid approximately $24,820.64 in finder fees and issued 496,413 finder's options.

Hemostemix announces the launch of a social media campaign to promote and sell ACP-01 treatments under special access programs for various cardiovascular conditions. ACP-01, proven safe in 498 treatments across six clinical trials and one retrospective study with 318 subjects, has shown significant results. Notable outcomes include up to 47.1% improvement in cardiac function for dilated cardiomyopathy patients and 83% healing rate in CLTI patients. Recent CIHI data reveals concerning statistics about diabetes-related amputations, including 7,720 hospitalizations for lower limb amputations, with average hospitalization costs of $47,000 and annual costs reaching $750 Million.